Technical Analysis for PLUR - Pluri Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 50 DMA | Bearish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Crossed Above 50 DMA | Bullish | -2.71% | |
| Upper Bollinger Band Walk | Strength | -2.71% | |
| Wide Bands | Range Expansion | -2.71% | |
| Overbought Stochastic | Strength | -2.71% | |
| Upper Bollinger Band Touch | Strength | -2.71% | |
| Fell Below 50 DMA | Bearish | 0.16% |
| Alert | Time |
|---|---|
| 10 DMA Support | 1 day ago |
| 50 DMA Support | 1 day ago |
| Down 5% | 1 day ago |
| Down 3% | 1 day ago |
| Up 3% | 1 day ago |
Get this analysis on your stocks daily!
- Earnings date: 06/25/2024
Pluri Inc. Description
Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Surgery Stem Cell Cell Therapy Radiation Transplantation Inflammatory Transplantation Medicine Host Disease Acute Respiratory Distress Syndrome Graft Versus Host Disease Covid 19 Cell Therapy Products Surgical Oncology
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.56 |
| 52 Week Low | 3.4488 |
| Average Volume | 32,080 |
| 200-Day Moving Average | 5.35 |
| 50-Day Moving Average | 6.20 |
| 20-Day Moving Average | 5.66 |
| 10-Day Moving Average | 6.03 |
| Average True Range | 0.46 |
| RSI (14) | 54.95 |
| ADX | 16.4 |
| +DI | 22.29 |
| -DI | 14.06 |
| Chandelier Exit (Long, 3 ATRs) | 5.16 |
| Chandelier Exit (Short, 3 ATRs) | 6.12 |
| Upper Bollinger Bands | 6.56 |
| Lower Bollinger Band | 4.76 |
| Percent B (%b) | 0.74 |
| BandWidth | 31.79 |
| MACD Line | 0.10 |
| MACD Signal Line | 0.00 |
| MACD Histogram | 0.1027 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.91 | ||||
| Resistance 3 (R3) | 6.95 | 6.71 | 6.78 | ||
| Resistance 2 (R2) | 6.71 | 6.51 | 6.70 | 6.73 | |
| Resistance 1 (R1) | 6.41 | 6.38 | 6.29 | 6.37 | 6.68 |
| Pivot Point | 6.17 | 6.17 | 6.12 | 6.16 | 6.17 |
| Support 1 (S1) | 5.87 | 5.97 | 5.75 | 5.83 | 5.52 |
| Support 2 (S2) | 5.63 | 5.84 | 5.62 | 5.47 | |
| Support 3 (S3) | 5.33 | 5.63 | 5.43 | ||
| Support 4 (S4) | 5.29 |
